Background. Standard 2-tiered immunoglobulin G (IgG) testing has performed well in late Lyme disease (LD), but IgM testing early in the illness has been problematic. IgG VlsE antibody testing, by itself, improves early sensitivity, but may lower specificity. We studied whether elements of the 2 approaches could be combined to produce a second-tier IgG blot that performs well throughout the infection.
when the first-tier test is positive or equivocal [2] . Sonicates of whole Borrelia burgdorferi are usually used as the antigen preparation in Western blots.
This approach has performed well for patients with late manifestations of LD, particularly in those with Lyme arthritis or late neuroborreliosis (stage 3) [3, 4] . Such patients have robust IgG antibody responses against many spirochetal antigens. However, the antibody responses in LD develop slowly, and therefore, antibody testing for patients with erythema migrans (EM) (stage 1) is insensitive and depends heavily on the detection of specific IgM responses [3, 4] . Although the current CDC guidelines limit the application of IgM criteria to the first 1 month of illness [2] , these criteria, which require 2 of 3 specific bands, have been problematic. Misuse or misinterpretation of IgM blots has been a factor in the overdiagnosis of LD for patients with other illnesses [5] [6] [7] [8] [9] [10] [11] .
In an effort to improve serologic testing, second generation tests that employ recombinant spirochetal proteins or synthetic peptides have been developed. Currently, the most promising tests use the VlsE (variable major protein-like sequence expressed) protein of B. burgdorferi, or a portion of it, as the antigen target in EIA tests. In initial retrospective studies, IgG EIAs using either recombinant VlsE (rVlsE) [12, 13] , or a 26-mer peptide from its sixth invariable (C6) region [13] [14] [15] , gave results similar to 2-tiered testing with whole-cell EIA and IgM and IgG immunoblots. Moreover, in a recent prospective study, a C6 test was more sensitive for patients with EM than standard 2-tiered testing [4] . However, a few patients with late disease lacked reactivity with the C6 peptide, and the test was less specific than the 2-tiered approach [4] , though these differences were not statistically significant.
In this study, our goal was to determine whether elements of the 2 approaches could be combined (sonicate EIA and IgG Western blot with a rVlsE band) to produce a 2-tiered IgG test that would perform at least as well as standard testing, without the drawbacks of IgM Western blot testing.
PATIENTS AND METHODS
Study subjects. The Human Investigations Committees at Massachusetts General Hospital (MGH), New York Medical College and CDC approved the study. All patients categorized as having LD met the CDC surveillance criteria for the diagnosis [16] .
At MGH, the antibody assays were evaluated using a total of 433 serum samples from 354 subjects. These included all remaining samples available from a set collected prospectively between 1999 and 2001, and stored frozen at Ϫ80ЊC. For this study, the set consisted of acute and convalescent serum samples from 79 patients with culture-confirmed EM. In addition, one pretreatment specimen was tested from each of 35 patients with active nervous system, heart or joint involvement. Samples were also included from 74 patients (with or without a history of LD) who did not currently meet criteria for LD. Finally, samples were tested from 166 healthy control subjects, 66 from areas of LD endemicity and 100 from New Zealand, a nonendemic region. These samples, except for those from New Zealand, were originally tested by other methods, and the results were reported previously [4] .
At Westchester Medical Center (WMC), the antibody assays were evaluated using 104 serum samples from 77 patients or control subjects. Serum samples from patients with EM of short duration (р14 days) were selected from a larger group of 257 serum samples, which were collected between 1991 and 1992 and stored frozen at Ϫ80ЊC. Serologic analysis of these materials was previously published [17] . For this study, the set included acute and convalescent serum samples from 27 subjects with culture-confirmed EM. In addition, one pretreatment sample was included from each of 15 subjects with early neurologic, heart or joint involvement, collected between 1993 and 2007. For comparison, serum samples from 29 subjects with other illnesses were tested; 10 had rheumatoid arthritis, 10 had systemic lupus erythematosus, and 9 had syphilis.
Serologic testing. In both laboratories, all samples were tested by whole-cell EIA and separate IgM and IgG Western blots. Prior to testing, all samples in both laboratories were coded and randomized. Samples in the MGH serum sample set were first tested at CDC using the VIDAS Lyme IgG and IgM polyvalent assay (bioMérieux SA), except for the samples from New Zealand, which were tested at MGH using the same assay. Serum samples in the WMC serum sample set were first tested at WMC using the Wampole B. burgdorferi IgG/M ELISA II assay (Inverness Medical Professional Diagnostics). All testing was performed according to the manufacturer's instructions.
For Western blotting, all samples in both laboratories, whether positive or negative by EIA, were analyzed using the Borrelia B31 IgM Virablot and the Borrelia B31 IgG Virablot plus VlsE (Viramed Biotech AG), according to the manufacturer's instructions. The Virablots were prepared from wholecell cultures of B. burgdorferi strain B31, and a recombinant VlsE (rVlsE) band was applied directly to the IgG blots. The MGH serum set was tested at MGH; the WMC set was tested at WMC. At MGH, the immunoblots were read with the aid of densitometry, whereas at WMC, they were read visually using a weak cutoff control provided by the manufacturer. When band intensities were measured using densitometry, a band was defined as positive if its intensity was у90% of the cutoff control band's intensity.
Statistical analysis. Differences between proportions were considered significant if the 2-tailed P value was р.05, as determined using the Fisher exact test; 95% confidence intervals (CIs) of proportions were calculated using the "exact" method. Optimal interpretive criteria for 2-tiered testing using only IgG blots as the second test were determined using receiver operating characteristic (ROC) curves, in which sensitivity was plotted against 1-specificity. Areas under the ROC curves were compared using the method described by DeLong et al [18] .
RESULTS

Standard 2-tiered testing.
The data were first analyzed using the standard 2-tiered CDC-recommended algorithm [2] . Although Western blots were performed on all serum samples, a positive result by 2-tiered testing required both a positive or equivocal EIA result and a positive immunoblot. Furthermore, patient samples that met IgM criteria, but not IgG criteria, were only considered positive if the duration of illness was р1 month.
Similar results were obtained using separate serum sets in the laboratories at MGH and WMC (Tables 1 and 2 ). With both serum sets, about one-third of patients with active EM (stage 1), which had been present for a median duration of 3- 17 (100) 1 (6) 12 (71) 13 (76) 13 (76) 13 (76) No history of Lyme disease ( ) n p 57 4 (7) IgM blot were considered negative by 2-tiered criteria, because they had been ill 11 month (5-16 weeks) at the time of collection of serum samples. Even though they did not yet have the у5 bands required for a positive IgG blot, both their IgM and IgG blots typically showed reactivity with the 23-kD, 39-kD, and 41-kD spirochetal proteins, which are common early responses. All patients with stage 3 LD, which occurred months to several years after disease onset, had positive IgG blots, and they typically had reactivity with 7-10 of the 10-scored spirochetal proteins. For patients with other illnesses who had no past history of LD and in healthy control subjects from endemic or nonendemic areas for the infection, the specificity of both IgM and IgG 2-tiered testing was 100% (95% CI, 98.8%-100%). The only result that was significantly different between the 2 laboratories was the sensitivity of IgM Western blots for patients who were convalescent from EM (78% at WMC vs 54% at MGH; ) (Tables 1 and 2 ). This discrepancy was not P p .04 explained by differences between patient groups. In both groups, the median duration of symptoms prior to treatment was 3-4 days, and convalescent serum samples were obtained 3-4 weeks after the initiation of antibiotic therapy. The proportion of patients with evidence of hematogenous dissemination, as assessed by the number of patients with multiple EM lesions (the only marker that was available in both sets of patients) was higher in the MGH set (19%) than in the WMC set (7%) ( ), which is the opposite of what would be P ! .001 expected if this factor were important in explaining the higher frequency of seroreactivity in the WMC set.
When the results of standard 2-tiered testing were compared with those obtained with the VlsE band alone, the VlsE band gave higher sensitivity for patients with stage 1 or stage 2 LD (Tables 1 and 2 ). On the other hand, there were a few patients with EM who had positive IgM blots who did not yet have IgG reactivity with the VlsE band. In addition, one patient with acute neuroborreliosis (stage 2) and one with Lyme arthritis (stage 3) lacked reactivity with VlsE. Finally, a few patients in the control groups had responses to the VlsE band alone, usually without or with minimal reactivity to other spirochetal proteins. Thus, not all patients who had IgM or IgG responses with 2-tiered testing had reactivity with the VlsE band, and the VlsE test had slightly lower specificity in the control groups than standard 2-tiered testing.
Algorithms using IgG blots, without IgM blots, as a secondtier test. The first alternative considered was an IgG blot (with a VlsE band), without an IgM blot, as the second test in a 2-tiered algorithm for use in all stages of the illness (Table 3; modified IgG 2-tier testing). ROC curves showed that inclusion of the VlsE band in the IgG blot resulted in greater area under the curve for IgG testing in all stages of LD, compared with CDC-recommended criteria ( ; Figure 1) . With a re-P ! .001 quirement of у99% specificity, the greatest sensitivity was achieved using a cutoff of 3 of 11 specific IgG bands (18, 23, 28 , 30, 39, 41, 45, 58, 66, and 93 kD plus VlsE). However, compared with standard 2-tiered IgM and IgG testing, there was still considerable loss of sensitivity in stage 1 LD.
The second alterative scored the VlsE band alone as the second test in a 2-tiered algorithm for use in all stages of the illness (Table 3 ; VlsE Band 2-tier testing). With this approach, sensitivity was similar to standard 2-tiered testing for patients with stage 1 or stage 3 LD, but was significantly improved in those with stage 2 disease. Because no control subject had a positive result with both the whole-cell EIA and the VlsE band, the specificity of this 2-tiered approach was 100% (95% CI, 98.8%-100%). Nevertheless, one patient each with acute neuroborreliosis or Lyme arthritis lacked reactivity with the VlsE band.
The third alternative was a hybrid approach, which combined advantageous aspects of the previous 2 approaches. For early infection (stages 1 and 2), the VlsE band alone was used as the second-tier test, but for late infection (stage 3), all 11 bands were scored. For stage 3 LD, high specificity (199%) and sensitivity (100%) was achieved using a cutoff ranging from 3 to 7 of the 11 IgG bands. We chose to use a cutoff of 5 of the 11 bands (18, 23, 28, 30, 39, 41, 45 , 58, 66, and 93 kD plus VlsE) because 5 bands has worked well in the standard CDC criteria, and requiring a smaller number of bands for a positive result would magnify the problem of misreading faint bands.
With this hybrid approach, 34% of patients with acute EM, 96% of those with acute neuroborreliosis or carditis, and 100% of those with Lyme arthritis or late neurologic involvement had positive responses (Table 3 ; hybrid IgG 2-tier testing). Compared with standard 2-tiered IgM and IgG testing, the hybrid approach allowed slightly better sensitivity in stage 1 (34% vs 31%), significantly greater sensitivity in stage 2 (96% vs 63%;
), comparable sensitivity in stage 3 (100% for both), P p .005 and equivalent specificity (100%; 95% CI, 98.8%-100%) among the control groups.
DISCUSSION
Using standard 2-tiered testing, about one-third of the patients in this study with active EM (stage 1) had antibody responses to B. burgdorferi, primarily based on a positive IgM immunoblot; approximately two-thirds with acute neuroborreliosis or carditis (stage 2) had positive results, and all patients with Lyme arthritis or late neurological involvement (stage 3) had positive results (invariably including a positive IgG immunoblot). Using separate serum sets, both study laboratories obtained remarkably similar results. Of particular interest, both laboratories achieved 100% specificity in reading IgM and IgG blots in control populations. This shows that IgM criteria can be used successfully, using either visual methods (as at WMC) or densitometric methods (as at MGH) to score the blots.
In practice, IgM testing in LD has been problematic. First, patients with certain other illnesses, including human granulocytic anaplasmosis or Epstein-Barr virus infection, may have positive IgM blots to B. burgdorferi antigens [8] . Second, to reduce the problem of false-positive IgM results, the CDC guidelines state that IgM criteria should only be used to support the diagnosis of early LD in persons with illness of р1-month duration. However, as shown here, this requirement reduces the sensitivity of serologic testing for patients with stage 2 acute neuroborreliosis who have had symptoms for several weeks longer than 1 month. Finally, in our experience, some laboratories have difficulty reading IgM blots, and over-interpret faint bands, which reduces specificity. Although densitometric analysis of bands may reduce observer variability, blots still require visual inspection to verify the results [19] . Thus, it would be advantageous if criteria could be developed that eliminated the need for IgM testing.
Since results of enzyme-linked immunosorbent assays using VlsE or its C6 peptide have been similar to those of standard 2-tiered IgM and IgG testing [4, 13] , consideration has been given to using a VlsE or C6 peptide assay as a stand-alone test in place of standard 2-tiered testing. However, not all patients, including some with late disease, have a response to the C6 peptide [4, 20] , and the C6 assay, when used as a stand-alone test, was not quite as specific as standard 2-tiered testing [4] . Because misdiagnosis has been a major problem in LD [5, 21, 22] , we sought to develop an approach that does not rely on antibody responses to a single antigen.
In the current study, we assessed whether test performance could be improved using a sonicate EIA followed by an IgG Western blot with a VlsE band. ROC curves showed the greatest sensitivity and specificity were achieved with criteria requiring any 3 of 11 IgG bands for use in any stage of the illness. Compared with standard 2-tiered testing, these criteria improved the sensitivity of testing for patients with acute neuroborreliosis or carditis (stage 2), but sensitivity remained a problem in those with EM (stage 1). Moreover, given the experience with overinterpreting 2 of 3 faint bands on IgM blots, we were concerned about criteria that would require only 3 of 11 IgG bands.
We next tested a 2-tiered algorithm that required only the VlsE band as a second-tier test. This approach improved sensitivity in stages 1 and 2 LD, but reduced it slightly in stage 3 infection. Specificity was 100% because no control subject in this study had a positive result with both the whole-cell EIA and the VlsE band. However, additional patients will need to be tested to be certain that this observation holds up in larger populations. Moreover, using only 1 band to support the diagnosis of LD might lead to even greater reliability problems than criteria using 3 of 11 IgG bands. However, it is possible that this approach could be developed in a format in which the result is more objective, using a VlsE or C6 peptide enzymelinked immunosorbent assay as a second-tier test [23, 24] .
The best test performance here was achieved by combining advantageous aspects of the 2 previous approaches. Using hybrid IgG criteria, in which only the VlsE band was scored as a second-tier test for patients with early LD (stage 1 or stage 2) and at least 5 of 11 IgG bands were required for patients with late LD (stage 3), sensitivity and specificity were comparable to or better than standard 2-tiered testing. Even though the proposed new criteria require only a positive EIA and VlsE band for stage 1 or stage 2 LD, patients with stage 2 disease typically have reactivity with more bands than the VlsE protein alone, including the 23-kD, 39-kD, and 41-kD spirochetal proteins. Therefore, if one is considering whether a patient has stage 2 acute neuroborreliosis, then reactivity with only the VlsE band is likely to be a false-positive result. By stage 3, all LD patients had not only 5, but usually у7 specific IgG bands. Although this hybrid approach still requires 2 sets of IgG blot criteria, one for early disease (stage 1 or stage 2) and the other for late disease (stage 3), it removes the cutoff of 1 month of symptoms, which is often difficult to determine.
In summary, 2-tiered IgG testing, as proposed here, removes the drawbacks of IgM testing in LD. Compared with standard IgM and IgG testing, the proposed system has equivalent sensitivity in stages 1 and 3 LD, significantly better sensitivity in stage 2 disease, and equivalent specificity in all control groups.
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